Eikon Therapeutics Stock Forecast
NASDAQ: EIKNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 7.50 0.00%
EIKN analyst consensus
Consensus (6 analysts)
none
Avg. price target
$24.60+228.00%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Eikon Therapeutics (2026-10-08), 5 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $24.60, with a high estimate of $32.00 and a low estimate of $4.00. The average target implies upside of 228.0% from the current price of $7.50.
The spread between the highest and lowest targets is 700.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for EIKN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 33% |
| Buy | 3 | 50% |
| Hold | 0 | 0% |
| Sell | 1 | 17% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | -46.67% |
| Average target | $24.60 | +228.00% |
| High target | $32.00 | +326.67% |